Herr Prof. Dr. med. Schmiegel

Herr Prof. Dr. med. Schmiegel

FA für Innere Medizin, Gastroenterologie, Endokrinologie, Hämatologie/ internistische Onkologie

Anschrift

Medizinische Universitätsklinik
Knappschaftskrankenhaus
In der Schornau 23 – 25
44892 Bochum

Kontakt

• Tel.:+49 (0)234 / 299-3401
• Fax:+49 (0)234 / 299-3409
• meduni-kkh@ruhr-uni-bochum.de

Klinische Schwerpunkte

Beruflicher und wissenschaftlicher Werdegang:

1970 – 1977 Medizinstudium in Löwen/Belgien,
Ruhr-Universität Bochum, Rheinische Friedrich-Wilhelm-Universität Bonn

1977 – 1978 Medizinalassistent im Allgemeinen Krankenhaus St. Georg, Hamburg


1978 Promotion an der Universität Essen

1978 Approbation als Arzt

1978 – 1990 Wissenschaftlicher Assistent, Medizinische Klinik, Universitätskrankenhaus Eppendorf (UKE), Hamburg
Anerkennung als Arzt für Innere Medizin und Teilgebiete Gastroenterologie; Endokrinologie; Hämatologie / internistische Onkologie

1988 Habilitation und venia legendi für das Fach Innere Medizin, UKE Hamburg

1990 – 1993 Oberarzt der I. Medizinischen Universitätsklinik und Poliklinik UKE Hamburg

1993 Berufung auf eine C3-Professur (Innere Medizin, Gastroenterologie-Hepatologie, Gastroenterologische
Onkologie) durch die Universität Hamburg

1993 - Berufung als Universitätsprofessor und Direktor der
Medizinischen Universitätsklinik Knappschaftskrankenhaus,Ruhr-Universität Bochum

Befugnis zur Weiterbildung in der

• Fachkunde Internistische Röntgendiagnostik
• Fachkunde in Laboruntersuchungen in der Inneren Medizin
• 
  
  Befristete Weiterbildungen bis zum 31.12.2007 für:
  
• Intensivmedizin
• Innere Medizin und Gastroenterologie
• Innere Medizin und Allgemeinmedizin
• Infektiologie
• 
  
  2002 - Direktor Abteilung Gastroenterologie/Hepatologie,
  Universitätsklinik Bergmannsheil,Ruhr-Universität Bochum
  
  1999-2003 Ärztlicher Direktor Universitätsklinik
  Knappschaftskrankenhaus
  
  2007-2009 Ärztlicher Direktor Universitätsklinik
  Knappschaftskrankenhaus
  
  Auszeichnungen:
  
  · G. E. Konjetzny Preis (1988)
  · Dr. Martini Preis (1989)
  · Stiftung zur Förderung der Innovation in Wissenschaft und Forschung NRW Preis (1994)
  . Charles Moertel Award in Digestive Oncology (IDCA/World Gastroenterology Organisation) (2007)

  Wissenschaftliche Schwerpunkte

  Mitgliedschaften in wissenschaftlichen Fachgesellschaften:
  
  Charles Moertel Award
  
  Gesellschaft für Immunologie, Deutsche Gesellschaft für Verdauungs- und
  Stoffwechselkrankheiten (DGVS), Deutsche Gesellschaft für Innere Medizin (DGIM), American Gastroenterological Association (GASL), German Association for the Study of Liver Diseases (AASLD), American Association for the Study of Liver Diseases (AASLD), American Association for Cancer Research (AACR), American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO), Deutsche Krebsgesellschaft (DKG/AIO)
  
  Mitgliedschaften in wissenschaftlichen Gremien:
  1993 – 2000 Sprecher der Arbeitsgemeinschaft Gastroenterologische Onkologie der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten (DGVS)
  
  1993 - Beirat DGVS
  
  1999 - Medizinischer Beirat der Deutschen Krebshilfe (DKH)
  
  2000 - 2004 Sprecher der Leitlinienkommission Krebstherapiestudien
  
  2000 - Wissenschaftlicher Beirat der Bundesärztekammer
  
  2001 - Sekretär und Vorstandsmitglied der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten
  
  2001 - 2004 Senatsausschuss Deutsche Forschungsgemeinschaft f. d. Sonderforschungsbereiche
  
  2003 - 2007 Lenkungsausschuss des Nationalen Genom-Forschungsnetzes (NGFN) der Bundesregierung
  
  2005 - Wissenschaftlicher Beirat IZKF Universitätsklinik
  Erlangen
  
  2007 Präsident der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten
  
  2006 - Councillor United European Gastroenterology Foundation (UEGF)
  
  2008- Vorstand Deutsche Krebsgesellschaft
  
  2009- Secretary General European Society of Digestive Oncology (ESDO)
  
  2009- Nationaler Krebsplan (BMG, DKG, DKH, ADT)-Steuerkreis
  
  2009- Mitglied des Sientific Committee of United European
  Gastroenterology Foundation (UEGF)
  
  2010 Kongresspräsident der Deutschen Krebsgeselschaft

  Publikationen

  Originalarbeiten
  July 2011
  
  Characterization of soluble and exosomal forms of the EGFR released from pancreatic cancer cells.Adamczyk KA, Klein-Scory S, Tehrani MM, Warnken U, Schmiegel W, Schnölzer M, Schwarte-Waldhoff I.
  Life Sci. 2011 Jul 6. [Epub ahead of print]
  
  
  Prognostic value of reduced SMAD4 expression in patients with metastatic colorectal cancer under oxaliplatin-containing chemotherapy: a translational study of the AIO colorectal study group.Baraniskin A, Munding J, Schulmann K, Meier D, Porschen R, Arkenau HT, Graeven U, Schmiegel W, Tannapfel A, Reinacher-Schick A.
  Clin Colorectal Cancer. 2011 Mar 1;10(1):24-9.
  
  
  [In Process Citation].
  Arnold D, Fietkau R, Hegewisch-Becker S, Höhler T, Knoefel WT, Kubicka S, Lang H, Liersch T, Luster M, Oettle H, Reinacher-Schick A, Ridwelski K, Riess H, Rödel C, Rüschoff J, Schmiegel W, Schmoll HJ, Vanhoefer U.
  Onkologie. 2011;34 Suppl 3:1-31. Epub 2011 Apr 27. German. No abstract available.
  
  
  Keratin 23, a novel DPC4/Smad4 target gene which binds 14-3-3ε.Liffers ST, Maghnouj A, Munding JB, Jackstadt R, Herbrand U, Schulenborg T, Marcus K, Klein-Scory S, Schmiegel W, Schwarte-Waldhoff I, Meyer HE, Stühler K, Hahn SA.
  BMC Cancer. 2011 Apr 14;11:137.
  
  
  German S3-guideline "Diagnosis and treatment of esophagogastric cancer"].
  Moehler M, Al-Batran SE, Andus T, Anthuber M, Arends J, Arnold D, Aust D, Baier P, Baretton G, Bernhardt J, Boeing H, Böhle E, Bokemeyer C, Bornschein J, Budach W, Burmester E, Caca K, Diemer WA, Dietrich CF, Ebert M, Eickhoff A, Ell C, Fahlke J, Feussner H, Fietkau R, Fischbach W, Fleig W, Flentje M, Gabbert HE, Galle PR, Geissler M, Gockel I, Graeven U, Grenacher L, Gross S, Hartmann JT, Heike M, Heinemann V, Herbst B, Herrmann T, Höcht S, Hofheinz RD, Höfler H, Höhler T, Hölscher AH, Horneber M, Hübner J, Izbicki JR, Jakobs R, Jenssen C, Kanzler S, Keller M, Kiesslich R, Klautke G, Körber J, Krause BJ, Kuhn C, Kullmann F, Lang H, Link H, Lordick F, Ludwig K, Lutz M, Mahlberg R, Malfertheiner P, Merkel S, Messmann H, Meyer HJ, Mönig S, Piso P, Pistorius S, Porschen R, Rabenstein T, Reichardt P, Ridwelski K, Röcken C, Roetzer I, Rohr P, Schepp W, Schlag PM, Schmid RM, Schmidberger H, Schmiegel WH, Schmoll HJ, Schuch G, Schuhmacher C, Schütte K, Schwenk W, Selgrad M, Sendler A, Seraphin J, Seufferlein T, Stahl M, Stein H, Stoll C, Stuschke M, Tannapfel A, Tholen R, Thuss-Patience P, Treml K, Vanhoefer U, Vieth M, Vogelsang H, Wagner D, Wedding U, Weimann A, Wilke H, Wittekind C; AWMF.
  Z Gastroenterol. 2011 Apr;49(4):461-531. Epub 2011 Apr 7. German. No abstract available.
  
  
  Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system.Baraniskin A, Kuhnhenn J, Schlegel U, Chan A, Deckert M, Gold R, Maghnouj A, Zöllner H, Reinacher-Schick A, Schmiegel W, Hahn SA, Schroers R.
  Blood. 2011 Mar 17;117(11):3140-6. Epub 2011 Jan 3.
  
  Psychological impact of genetic counseling for hereditary nonpolyposis colorectal cancer: the role of cancer history, gender, age, and psychological distress.Hasenbring MI, Kreddig N, Deges G, Epplen JT, Kunstmann E, Stemmler S, Schulmann K, Willert J, Schmiegel W.
  Genet Test Mol Biomarkers. 2011 Apr;15(4):219-25. Epub 2010 Dec 31.
  
  
  Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy.Goede V, Coutelle O, Neuneier J, Reinacher-Schick A, Schnell R, Koslowsky TC, Weihrauch MR, Cremer B, Kashkar H, Odenthal M, Augustin HG, Schmiegel W, Hallek M, Hacker UT.
  Br J Cancer. 2010 Oct 26;103(9):1407-14. Epub 2010 Oct 5.
  
  
  Gastrointestinal bleeding 30 years after a complicated cholecystectomy.Brechmann T, Schmiegel W, Nicolas V, Reiser M.
  World J Gastroenterol. 2010 Oct 7;16(37):4747-50.
  
  
  Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial.Dollinger MM, Lautenschlaeger C, Lesske J, Tannapfel A, Wagner AD, Schoppmeyer K, Nehls O, Welker MW, Wiest R, Fleig WE; AIO Hepatobiliary Study Group.
  BMC Cancer. 2010 Aug 24;10:457.
  
  
  Diagnosis of leptomeningeal disease in diffuse large B-cell lymphomas of the central nervous system by flow cytometry and cytopathology.Schroers R, Baraniskin A, Heute C, Vorgerd M, Brunn A, Kuhnhenn J, Kowoll A, Alekseyev A, Schmiegel W, Schlegel U, Deckert M, Pels H.
  Eur J Haematol. 2010 Dec;85(6):520-8. doi: 10.1111/j.1600-0609.2010.01516.x. Epub 2010 Oct 28
  
  
  SMAD4 mediates mesenchymal-epithelial reversion in SW480 colon carcinoma cells.Pohl M, Radacz Y, Pawlik N, Schoeneck A, Baldus SE, Munding J, Schmiegel W, Schwarte-Waldhoff I, Reinacher-Schick A.
  Anticancer Res. 2010 Jul;30(7):2603-13.
  
  
  Efficacy of recombinant adeno-associated viral vectors serotypes 1, 2, and 5 for the transduction of pancreatic and colon carcinoma cells.Teschendorf C, Emons B, Muzyczka N, Graeven U, Schmiegel W.
  Anticancer Res. 2010 Jun;30(6):1931-5.
  
  
  A rare case of chronic lymphocytic leukemia with hypercalcemia induced by elevated parathyroid hormone-related peptides.Kampfenkel T, Baraniskin A, Teschendorf C, Schmiegel W, Massenkeil G.
  Acta Haematol. 2010;124(1):57-60. Epub 2010 Jul 9.
  
  
  Peri-operative chemotherapy for the treatment of resectable liver metastases from colorectal cancer: A systematic review and meta-analysis of randomized trials.
  Wieser M, Sauerland S, Arnold D, Schmiegel W, Reinacher-Schick A.
  BMC Cancer. 2010 Jun 21;10:309. Review.
  
  
  Molecular markers and biological targeted therapies in metastatic colorectal cancer: expert opinion and recommendations derived from the 11th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2009.
  Van Cutsem E, Dicato M, Arber N, Berlin J, Cervantes A, Ciardiello F, De Gramont A, Diaz-Rubio E, Ducreux M, Geva R, Glimelius B, Glynne Jones R, Grothey A, Gruenberger T, Haller D, Haustermans K, Labianca R, Lenz HJ, Minsky B, Nordlinger B, Ohtsu A, Pavlidis N, Rougier P, Schmiegel W, Van de Velde C, Schmoll HJ, Sobrero A, Tabernero J.
  Ann Oncol. 2010 Jun;21 Suppl 6:vi1-10.
  
  
  
  
  
  
  
  Detection of free immunoglobulin light chains in cerebrospinal fluids of patients with central nervous system lymphomas.Schroers R, Baraniskin A, Heute C, Kuhnhenn J, Alekseyev A, Schmiegel W, Schlegel U, Pels HJ.
  Eur J Haematol. 2010 Sep;85(3):236-42. Epub 2010 May 26
  
  
  Soluble E-cadherin as a serum biomarker candidate: elevated levels in patients with late-stage colorectal carcinoma and FAP.Weiss JV, Klein-Scory S, Kübler S, Reinacher-Schick A, Stricker I, Schmiegel W, Schwarte-Waldhoff I.
  Int J Cancer. 2011 Mar 15;128(6):1384-92. doi: 10.1002/ijc.25438
  
  
  High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma.
  Glass B, Ziepert M, Reiser M, Freund M, Trümper L, Metzner B, Feller A, Loeffler M, Pfreundschuh M, Schmitz N; German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL).
  Ann Oncol. 2010 Nov;21(11):2255-61. Epub 2010 May 5.
  
  
  Role of CT colonography in colorectal cancer screening: risks and benefits.Pox CP, Schmiegel W.
  Gut. 2010 May;59(5):692-700. Review.
  
  
  Intravascular large B-cell lymphoma presenting as dementia and hemolytic anemia.Baraniskin A, Jähnert A, Ahle G, Theile A, Kretzschmar H, Schmiegel W, Schroers R.
  Onkologie. 2010;33(4):174-7. Epub 2010 Mar 19.
  
  Quantification of circulating endothelial progenitor cells in human peripheral blood: establishing a reliable flow cytometry protocol.Masouleh BK, Baraniskin A, Schmiegel W, Schroers R.
  J Immunol Methods. 2010 May 31;357(1-2):38-42. Epub 2010 Apr 8.
  
  Uncoupled responses of Smad4-deficient cancer cells to TNFalpha result in secretion of monomeric laminin-gamma2.
  Zboralski D, Warscheid B, Klein-Scory S, Malas MB, Becker H, Böckmann M, Meyer HE, Schmiegel W, Simon-Assmann P, Schwarte-Waldhoff I.
  Mol Cancer. 2010 Mar 22;9(1):65.
  
  
  Gefitinib in combination with capecitabine as second-line therapy in patients with advanced colorectal cancer (aCRC): a phase I/II study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
  Trarbach T, Reinacher-Schick A, Hegewisch-Becker S, Vanhoefer U, Frieling T, Lehnert L, Schmiegel W, Graeven U.
  Onkologie. 2010;33(3):89-93. Epub 2010 Feb 23
  
  Immunoscreening of the extracellular proteome of colorectal cancer cells.Klein-Scory S, Kübler S, Diehl H, Eilert-Micus C, Reinacher-Schick A, Stühler K, Warscheid B, Meyer HE, Schmiegel W, Schwarte-Waldhoff I.
  BMC Cancer. 2010 Feb 25;10:70.
  
  
  S3 guidelines for colorectal carcinoma: results of an evidence-based consensus conference on February 6/7, 2004 and June 8/9, 2007 (for the topics IV, VI and VII).
  Schmiegel W, Pox C, Reinacher-Schick A, Adler G, Arnold D, Fleig W, Fölsch UR, Frühmorgen P, Graeven U, Heinemann V, Hohenberger W, Holstege A, Junginger T, Kopp I, Kühlbacher T, Porschen R, Propping P, Riemann JF, Rödel C, Sauer R, Sauerbruch T, Schmitt W, Schmoll HJ, Seufferlein T, Zeitz M, Selbmann HK; Federal Committee of Physicians and Health Insurers.
  Z Gastroenterol. 2010 Jan;48(1):65-136. Epub 2010 Jan 13. No abstract available.
  
  
  Colorectal carcinoma: the management of polyps, (neo)adjuvant therapy, and the treatment of metastases.
  Schmiegel W, Pox C, Arnold D, Porschen R, Rödel C, Reinacher-Schick A; Association of the Scientific Medical Societies in Germany; German Cancer Aid; German Cancer Society; German Society for Digestive and Metabolic Diseases; German Society for General and Visceral Surgery; German Society for Hematology and Oncology; German Society for Pathology; German Society for Radiooncology; German Roentgen Society; German Joint Society for Clinical Chemistry and Laboratory Medicine; German Society for Coloproctology; Association of Stoma Patients and Persons with Intestinal Cancer; German Crohn's Disease and Ulcerative Colitis Association; German Society for Internal Medicine.
  Dtsch Arztebl Int. 2009 Dec;106(51-52):843-8. Epub 2009 Dec 18. Erratum in: Dtsch Arztebl Int. 2010 Feb;107(5):74.
  
  
  
  Identification and expression analysis of the aldo-ketoreductase1-B10 gene in primary malignant liver tumours.
  Heringlake S, Hofdmann M, Fiebeler A, Manns MP, Schmiegel W, Tannapfel A.
  J Hepatol. 2010 Feb;52(2):220-7. Epub 2009 Nov 25.
  
  
  Chemotherapy of colorectal cancer].
  Reinacher-Schick A, Pohl M, Schmiegel W.
  Internist (Berl). 2009 Nov;50(11):1239-52. German
  
  
  Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer.
  Engel C, Rahner N, Schulmann K, Holinski-Feder E, Goecke TO, Schackert HK, Kloor M, Steinke V, Vogelsang H, Möslein G, Görgens H, Dechant S, von Knebel Doeberitz M, Rüschoff J, Friedrichs N, Büttner R, Loeffler M, Propping P, Schmiegel W; German HNPCC Consortium.
  Clin Gastroenterol Hepatol. 2010 Feb;8(2):174-82. Epub 2009 Oct 14.
  
  
  Emergencies in hematology and oncology].
  Baraniskin A, Schmiegel W, Schroers R.
  Dtsch Med Wochenschr. 2009 Sep;134(38):1879-88; quiz 1889-92. Epub 2009 Sep 10. Review. German. No abstract available.
  
  
  Truncating mutations in Peutz-Jeghers syndrome are associated with more polyps, surgical interventions and cancers.Salloch H, Reinacher-Schick A, Schulmann K, Pox C, Willert J, Tannapfel A, Heringlake S, Goecke TO, Aretz S, Stemmler S, Schmiegel W.
  Int J Colorectal Dis. 2010 Jan;25(1):97-107. Epub 2009 Sep 2
  
  
  Analysis of the pancreatic tumor progression by a quantitative proteomic approach and immunhistochemical validation.Sitek B, Sipos B, Alkatout I, Poschmann G, Stephan C, Schulenborg T, Marcus K, Lüttges J, Dittert DD, Baretton G, Schmiegel W, Hahn SA, Klöppel G, Meyer HE, Stühler K.
  J Proteome Res. 2009 Apr;8(4):1647-56.
  
  
  [Capsule endoscopy].Brechmann T, Schmiegel W.
  Med Klin (Munich). 2009 Jul 15;104(7):562-3. German. No abstract available.
  
  Bevacizumab plus oxaliplatin-based regimens for the treatment of colorectal cancer.Scheithauer W, Schmiegel W.
  Onkologie. 2009 Jul;32(7):431-9. Epub 2009 Jun 10. Review.
  
  Gastrointestinal tumors. Foreward].
  Schmoll HJ, Schmiegel W.
  Onkologie. 2009;32 Suppl 2:1. Epub 2009 Jun 22. German. No abstract available.
  
  
  Presumed cryptogenic liver disease in Germany: High prevalence of autoantibody-negative autoimmune hepatitis, low prevalence of NASH, no evidence for occult viral etiology.Heringlake S, Schütte A, Flemming P, Schmiegel W, Manns MP, Tillmann HL.
  Z Gastroenterol. 2009 May;47(5):417-23. Epub 2009 May 5.
  
  
  Antitumor activity of the HER2 dimerization inhibitor pertuzumab on human colon cancer cells in vitro and in vivo.
  Pohl M, Stricker I, Schoeneck A, Schulmann K, Klein-Scory S, Schwarte-Waldhoff I, Hasmann M, Tannapfel A, Schmiegel W, Reinacher-Schick A.
  J Cancer Res Clin Oncol. 2009 Oct;135(10):1377-86. Epub 2009 Apr 2.
  
  Gastrointestinal oncology - therapy update 2008 / 2009].
  Ebert MP, Auernhammer C, Caca K, Eckel F, Fischbach W, Geissler M, Göke B, Greten T, Kubicka S, Lutz MP, Möhler M, Opitz O, Pavel M, Porschen R, Reinacher-Schick A, Schmiegel W, Seufferlein T, Wiedenmann B, Schmid RM.
  Z Gastroenterol. 2009 Mar;47(3):296-306. Epub 2009 Mar 6. Review. German.
  
  Detection of novel biomarkers of liver cirrhosis by proteomic analysis.Moelleken C, Sitek B, Henkel C, Poschmann G, Sipos B, Wiese S, Warscheid B, Broelsch C, Reiser M, Friedman SL, Tornøe I, Schlosser A, Kloeppel G, Schmiegel W, Meyer HE, Holmskov U, Stuehler K
  Hepatology. 2009 Apr;49(4):1257-66.
  
  230 Mihaljevic A; Buchler P, Harder J; Hofheinz R; Gregor M, Kanzler S, Schmiegel W; Heinemann V, Endlicher E, Kloppel G, Seufferlein T, Geissler M. A prospective, non-randomized phase-II trial of Trastuzumab and Capecitabine in patients with HER2 expressing advanced pancreatic cancer. BMC Surg. 2009 Jan 8; 9 (1):1.
  
  229. Arkenau HT, Arnold D, Cassidy J, Diaz-Rubio E; Douillard JY, Hochster H, Martoni A, Grothey A, Hinke A, Schmiegel W, Schmoll HJ, Porschen R. Efficacy of oxaliplatin plus capecitabine or infusional flourourail/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol. 2008 Dec 20; 26 (36): 5910-5917
  
  228. Müller CI, Schulmann K, Reinacher-Schick A, Andre N, Arnold D, Tannapfel A, Arkenau H, Hahn SA, Schmoll HJ, Porschen R, Schmiegel W, Graeven U. Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a flouropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group. Int J Colorectal Dis. 2008 Nov 23; (11): 1033-1039
  
  227. Arnold D, Heinemann V, Hinke A, Grothey A, von Weikersthal LF, Kubicka S, Moosmann N, Reinacher-Schick A, Schmiegel W, Schmoll HJ. Waterfall plot analysis (WPA) for characterization of antitumor efficacy of capecitabine with oxaliplatin (CAPEOX) or with irinotecan (CAPEIRI), with or without Bevacizumab (B) or Cetuximab (C), in patients with untreated metastatic colorectal cancer (MCRC). Combined analysis of three randomized phase II trials of the AIO GI Group. Ann Oncol. 2008 Sep 8; 19: 138-138 Suppl.
  
  226. Schulmann K, Engel C, Propping P, Schmiegel W. Small bowel cancer risk in Lynch syndrome. GUT. 2008 Nov; 57 (11): 1629-1930
  
  225. Schmiegel W, Reinacher-Schick A, Arnold D, Graeven U, Heinemann V, Porschen R, Riemann J, Rödel C, Sauer R, Wieser M, Schmitt W, Schmoll HJ, Seufferlein T, Kopp I, Pox C. Update S3-Guideline „Colorectal Cancer“ 2008. Z Gastroenterol. 2008 Aug; 46(8): 799-840
  
  224. Reinacher-Schick A, Pohl M, Schmiegel W. Drug Insight: antiangiogenic therapies for gastrointestinal cancers-focus on monoclonal antibodies. Nat Clin Pract Gastroenterol Hepatol. 2008 Sep; 5 (9): 531-531
  
  223. Zboralski D, Böckmann M, Zapatka M, Hoppe S, Schöneck A, Hahn SA, Schmiegel W, Schwarte-Waldhoff I. Divergent mechanisms underlie Smad4-mediated positive regulation of the three genes encoding the basement membrane component laminin-332 (laminin-5). BMC Cancer, 2008 Jul 29; 8:215
  
  222. Zwick C, Birkmann J, Peter N, Bodenstein H, Fuchs R, Hänel M, Reiser M, Hensel M, Clemens M, Zeynalova S, Ziepert M, Pfreundschuh M, GermanHigh-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL). Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone). Ann Hematol. 2008 Sep; 87(9):717-26
  
  221. Sitek B, Sipos B, Klöppel G, Schmiegel W, Hahn SA, Meyer HE, Stühler K. Application of fluorescence dye saturation labeling for differential proteome analysis of 1,000 microdissected cells from pancreatic ductal adenocarcinoma precursor lesions. Methods Mol Biol. 2008;425:1-14
  
  220. Adler G, Seufferlein T, Bischoff SC, Brambs HJ, Feuerbach S, Grabenbauer G, Hahn S, Heinemann V, Hohenberger W, Langrehr JM, Lutz MP, Micke O, Neuhaus H, Neuhaus P, Oettle H, Schlag PM, Schmid R, Schmiegel W, Schlottmann K, Werner J, Wiedenmann B, Kopp I. S3-guideline “Exocrine Pancreatic Carcinoma” 2007 – Results of an evidence-based consensus conference (13.-14.10.2006). Z Gastroenterologie. 2008 May; 46 (5): 449-482
  
  219. Frystyk J, Ritzel RA, Maubach J, Büsing M, Lück R, Klempnauer J, Schmiegel W, Nauck MA. Comparison of pancreas-transplanted type 1 diabetic patients with portal-venous versus systemic-venous graft drainage: Impact on glucose regulatory hormones and the growth hormone/insulin-like growth factor-I axis. J Clin Endocrinol Metab. 2008 May; 93(5):1758-66
  
  218. Steinke V, Rahner N, Morak M, Keller G, Schackert HK, Görgens H, Schmiegel W, Royer-Pokora B, Dietmaier W, Kloor M, Engel C, Propping P, Aretz S, German HNPCC Consortium. No association between MUTYH and MSH6 germline mutations in 64 HNPCC patients. Eur J Hum Genet. 2008 May; 16(5):587-92
  
  217. Pox C, Schmiegel W. Colorectal Screening in Germany. Z Gastroenterol. 2008 Apr; 46: S31-32 Suppl 1
  216. Schulmann K, Engel C, Propping, Schmiegel W. Small Bowel Cancer risk in Lynch Syndrome. Gut, 2008 Mar; 26
  
  215. Arkenau HT, Graeven U, Kubicka S, Grothey A, Englisch-Kritz C, Kretzschmar A, Greil R, Freier W, Seufferlein T, Hinke A, Schmoll HJ, Schmiegel W, Porschen R; AIO Colorectal Study Group. Oxaliplatin in combination with 5-fluorouracil/leucovorin or capecitabine in elderly patients with metastatic colorectal cancer. Clin Colorectal Cancer, 2008 Jan;7(1):60-4
  
  214. Schmoll HJ, Schmiegel W. Preface Gastrointestinal Tumor. ONKOLOIGE; 2008, 31: V-V Suppl.
  
  213. Pox C, Schmiegel W. Protozoen; Bakterien; Infektionsprävention. Die ärztliche Begutachtung, 7. Aufl., Fritze J, Mehrhoff F (Hrsg)
  
  212. Moelleken C, Schmiegel W. Toxische Leberschädigung. Die ärztliche Begutachtung, 7. Aufl., Fritze J, Mehrhoff F (Hrsg.)
  
  211. Reiser M, Schmiegel W. Akute und chronische Virushepatitis. Die ärztliche Begutachtung, 7. Aufl., Fritze J, Mehrhoff F (Hrsg.)
  
  210. Heringlake S, Schmiegel W. Akute und chronische Pankreatitis. Die ärztliche Begutachtung, 7. Aufl., Fritze J, Mehrhoff F (Hrsg.)
  
  209. Henke H, Schmiegel W. Krankheiten von Speiseröhre und Magen. Die ärztliche Begutachtung, 7. Aufl., Fritze J, Mehrhoff F (Hrsg.)
  
  208. Brechmann T, Schmiegel W. Verdauungsorgane (Magen-Darm-Trakt, Bauchspreicheldrüse); Leber und Galle; Entzündliche Darmkrankheiten. Die ärztliche Begutachtung, 7. Aufl., Fritze J, Mehrhoff F (Hrsg.)
  
  207. Pox C, Schmiegel W, Nitschmann S. ASS in the prophylaxis of colorectal cancer. Internist (Berl) 2008 Mar; 49(3):360-2
  
  206. Porschen R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W, Kretzschmar A, Graeven U, Grothey A, Hinke A, Schmiegel W, Schmoll HJ. Capecitabine plus oxaliplatin in metastatic colorectal cancer – In reply. J Clin Oncol. 2007 Nov 1; 25 (31): 5045-5046
  
  205. Porschen R, Arkenau HT, Kubicka S, Greil R, Seufferlein T, Freier W, Kretzschmar A, Graeven U, Grothey A, Hinke A, Schmiegel W, Schmoll HJ. Comments on final report of the AIO colorectal cancer group study: Flourouracil/oxaliplatin versus capecitabine/oxaliplatin – In reply. J Clin Oncol. 2007 Nov 1; 25 (31): 5042-5043
  
  204. Klein-Scory S, Zapatka M, Eilert-Micus C, Hoppe S, Schwarz E, Schmiegel W, Hahn SA, Schwarte-Waldhoff I. High-level inducible Smad4-reexpression in the cervical cancer cell line C4-II is associated with a gene expression profile that predicts a preferential role of Smad4 in extracellular matrix composition. BMC Cancer 2007 Nov 12; 7:209
  
  203. Schulmann K, Pox C, Schmiegel W. Genetische Untersuchungen in der Gastroenterologie – Was ist wann sinnvoll und wirklich notwendig? Viszeralchirurgie 2007; 42:203-214
  
  202. Brechmann T, Heyer C, Schmiegel W. Methotrexate- induced pneumonitis in a woman with Crohn’s disease. Dtsch Med Wochenschr. 2007 Aug; 132(34-35):1759-62
  
  201. Reiser M, Haverkamp A, Dintsios M, Molleken C, Krauth C, Pieper W, Schmiegel W. Quality of care and health economics in occupationally acquired hepatit C in German health care workers between 1993 and 2004. Dtsch Med Wochenschr. 2007 Aug; 132(34-35):1743-7
  
  200. Schmiegel W. Gastroenterology as an interdisciplinary challenge. Dtsch Med Wochenschr. 2007 Aug; 132(34-35):1739
  
  199. Adler G, Seufferlein T, Bischoff SC, Brambs HJ, Feuerbach S, Grabenbauer G, Hahn S, Heinemann v, Hohenberger W, Langrehr JM, Lutz MP, Micke O, Neuhaus H, Neuhaus P, Oettle H, Schlag PM, Schmid R, Schmiegel W, Schlottmann K, Werner J, Wiedenmann B, Kopp I. Carcinoma of the pancreas: summary of guidelines 2007, issued jointly by 15 German specialist medical societies. Dtsch Med Wochenschr. 2007 Aug; 132(33):1696-700
  
  198. Brechmann T, Schmiegel W. Procedure of implementation of new methods of examination and treatment in the G-DRG system (NUB procedure). Med Klein. (Munich), 2007 Aug 15; 102(8):683-4
  
  197. Schulmann K, Pox C, Schmiegel W. Genetic analysis in gastroenterology – What makes sense and is necessary? Viszeralchirurgie. 2007 Aug; 42 (4): 203-214
  
  196. Adler G, Seufferlein T, Bischoff SC, Brambs HJ, Feuerbach S, Grabenbauer G, Hahn S, Heinemann V, Hohenberger W, Langrehr JM, Lutz MP, Micke O, Neuhaus H, Neuhaus P, Oettle H, Schlag PM, Schmid R, Schmiegel W, Schlottmann K, Werner J, Wiedenmann B, Kopp I. S3-Guidelines „Exocrine pancreatic cancer“ 2007. Z Gastroenterol. 2007 Jun; 45(6):487-523
  
  195. Griga T, Wilkens C, Wirkuns N, Epplen J, Schmiegel W, Klein W. A polymorphism in the macrophage migration inhibitory factor gene is involved in the genetic predisposition of Crohn’s disease and associated with cumulative steroid doses. Hepatogastroenterology 2007 Apr-May; 54(75):784-6
  
  194. Porschen R, Arkenau HAT, Kubicka S, Greil R, Seufferlein T, Freier W, Kretzschmar A, Graeven U, Grothey A, Hinke A, Schmiegel W, Schmoll HJ. Phase III study of Capecitabine Plus Oxaliplatin Compared with Fluorouracil and Leucovorin Plus Oxaliplatin Metastatic Colorectal Cancer: A Final Report of the AIO Colorectal Study Group. J Clin Oncol. 2007 Jun 4
  
  193. Schulmann K, Pox C, Tannapfel A, Schmiegel W. The patient with multiple intestinal polyps. Best Practice & Research Clinical Gastroenterology. 2007; 21, (3): 409-426
  
  192. Kaltz B, Bokemeyer B, Hoffmann J, Porschen R, Rogler G, Schmiegel W. Überwachungskoloskopie bei Colitis ulcerosa in Deutschland. Z Gastroenterol 2007; 45: 325 - 331
  
  191. Kaltz B, Bokemeyer B, Hoffmann J, Porschen R, Rogler G, Schmiegel W. Überwachungskoloskopie bei Colitis ulcerosa in Deutschland. Z Gastroenterol 2007; 45: 325 - 331
  190. Graeven U, Arnold D, Reinacher-Schick A, Heuer Th, Nusch A, Porschen R, Schmiegel W. A Randomised Phase II Study of Irinotecan in Combination with 5-FU/FA Compared with Irinotecan Alone as Second-Line Tretment of Patients with Metastatic Colorectal Carcinoma. Onkologie 2007;30:169-174
  189. Ritzel RA, Kleine N, Holst JJ, Willms B, Schmiegel W, Nauck MA. Preserved GLP-1 Effects in a Diabetic Patient with Cushing’s Disease. ESP Clin Endocrinol Diabetes 2007; 115 :146-150
  188. Diehl HC, Stuhler K, Klein-Scory S, Volmer, MW, Schoneck A, Bieling C, Schmiegel W, Meyer HE, Schwarte-Waldhoff I. A catalogue of proteins released by colorectal cancer cells in vitro as an alternative source for biomarker discovery. Proteomics Clin. Appl. 2007, 1, 47-61
  187. Pox C, Schmiegel W, Classen M. Current status of screening colonoscopy in Europe and in the United States. Endoscopy. 2007 Feb; 39 (2): 168-73
  186. Brechmann T, Massenkeil G, Schmiegel W. In Process Citation. Med Klin (Munich). 2007 Feb 15; 102 (2): 168-9
  185. Ritzel RA, Kleine N, Holst JJ, Willms B, Schmiegel W, Nauck MA. Preserved GLP-1 Effects in a Diabetic Patient with Cushing’s Disease. Exp Clin Endocrinol Diabetes. 2007 Feb; 115 (2): 146-50
  184. Basrai D, Pox C, Schmiegel W. Fever of intermediate duration after return from the Canary Islands. Internist (Berl). 2007 Feb 17
  183. Nauck MA, Reinecke M, Perren A, Frystyk J, Berishvili G, Zwimpfer C, Figge AM, Flyvbjerg A, Lankisch PG, Blum WF, Kloppel G, Schmiegel W, Zapf J. Hypoglycemia due to paraneoplastic Secretion of Insulin-like Growth Factor-I in a Patient with Metastasizing Large-Cell Carcinoma of the Lung. J Clin Endocrinol Metab. 2007 Feb 13
  182. Stuhler K, Koper K, Pfeiffer K, Tagariello A, Souquet M, Schwarte-Waldhoff I, Hahn SA, Schmiegel W, Meyer HE. Differential proteome analysis of colon carcinoma cell line SW480 after reconstitution of the tumour suppressor Smad4. Anal Bioanal Chem. 2006 Nov; 386 (6): 1603-12.
  181. Zapatka M, Zboralski D, Radacz Y, Bockmann M, Arnold C, Schoneck A, Hoppe S, Tannapfel A, Schmiegel W, Simon-Assmann R, Schwarte-Waldhoff I. Basement membrane component laminin-5 is a target of the tumor suppressor Smad4. Oncogene. 1007 Mar 1; 26 (10): 1417-27
  180. Goecke T, Schulmann K, Engel C, Holinski-Feder E, Pagenstecher C, Schackert HK, Kloor M, Kunstmann E, Vogelsang H, Keller G, Dietmaier W, Mangold E, Friedrichs N, Propping P, Kruger S, Gebert J, Schmiegel W, Rueschoff J, Loeffler M, Moeslein G, German HNPCC Consortium. Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC Consortium. J Clin Oncol. 2006 Sep 10; 24 (26): 4285-92
  179. Feldmann G, Nischalke HD, Nattermann J, Banas B, Berg T, Teschendorf C, Schmiegel W, Duhrsen U, Halangk J, Iwan A, Sauerbruch T, Caselmann WH, Spengler U. Induction of interleukin-6 by hepatitis C virus core protein in hepatitis C-associated mixed cryoglobulinemia and B-cell non-Hodgkin’s lymphoma. Clin Cancer Res. 2006 Aug 1; 12 (15): 4491-8
  178. Reinacher-Schick A, Schmiegel W. In Process Citation. Internist (Berl). 2006 Jun; 47 (6): 642-6
  177. Brechmann T, Walther J, Schmiegel W. Gastrointestinal hemorrhage. Med Klein (Munich). 2006 May 15; 101 (5): 406-7
  176. Reinacher-Schick A, Schmiegel W. Internist (Berl). 2006 May 4;
  175. Graeven U, Kremer B, Sudhoff T, Killing B, Rojo F, Weber D, Tillner J, Unal C, Schmiegel W. Phase I study of the humanised anti-EGFR monoclonal antibody matuzumab (EMD 72000) combined with gemcitabine in advanced pancreatic cancer. Br J Cancer. 2006 May 8; 94 (9): 1293-9
  174. Teschendorf C, Schmiegel W. Colorectal carcinoma in elderly patients. Schweiz Rundsch Med Prax. 2005 Dec 7; 94 (49): 1957-61
  173. Meier JJ, Deifuss S, Klamann A, Launhardt V, Schmiegel W, Nauck MA. Plasma glucose at hospital admission and previous metabolic control determine myocardial infarct size and survival in patients with and without type 2 diabetes: the Langendreer Myocardial Infarction and Blood Glucose in Diabetic Patients Assessment (LAMBDA). Diabetes Care. 2005 Oct; 28 (10): 2551-3
  172. Wagenleiter SE, Klein W, Griga T, Schmiegel W, Epplen JT, Jagiello P. A case-control study of tyrosine phosphatase (PTPN22) confirms the lack of association with Crohn’s disease. Int J Immunogenet. 2005 Oct; 32 (5): 323-4
  171. Buchholz M, Braun M, Heidenblut A, Kestler H A, Klöppel G, Schmiegel W, Hahn S A, Lüttges J, Gress T M. Transcriptome analysis of microdissected pancreatic intraepithelial neoplastic lesions. Oncogene 2005 Oct 6; 24: 6626-36
  170. Schulmann K, Mori Y, Croog V, Yin J, Olaru A, Sterian A, Sato F, Wang S, Xu Y, Deacu E, Berki AT, Hamilton JP, Kan T, Abraham JM, Schmiegel W, Harpaz N, Meltzer SJ. Molecular phenotype of inflammatory bowel disease-associated neoplasms with microsatellite instability. Gastroenterology. 2005 Jul; 129 (1): 74-85
  169. Andre N, Schmiegel W. Chemoradiotherapy for colorectal cancer. Gut. 2005 Aug; 548(8): 1194-202
  168. Bach K, Huppe D, Schmiegel W, Epplen JT, Kunstmann, E. Evaluation of outpatient management in HNPCC. Z Gastroenterol. 2005 Jul; 43 (7): 647-51
  167. Schmielau J, Teschendorf C, König M, Schmiegel W, Graeven U. Combination of bortezomib, thalidomide, and dexamethasone in the treatment of relapsed, refractory IgD multiple myeloma. Leukemia & Lymphoma 2005 Apr; 46 (4): 567-569
  166. Griga T, Wilkens C, Schmiegel W, Folwaczny C, Hagedorn M, Duerig N, Epplen J, Klein W. Association between the promoter polymorphism T/C at position –159 of the CD14 gene and anti-inflammatory therapy in patients with inflammatory bowel disease. Eur J Med Res. 2005 May 20; 10 (5): 183-6
  165. Sitek B, Luttges J, Marcus K, Kloppel G, Schmiegel W, Meyer HE, Hahn SA, Stuhler K. Application of fluorescence difference gel electrophoresis saturation labelling for the analysis of microdissected precursor lesions of pancreatic ductal adenocarcinoma. Proteomics. 2005 Jul; 5 (10): 2665-79
  164. Volmer MW, Stuhler K, Zapatka M, Schoneck A, Klein-Scory S, Schmiegel W, Meyer HE, Schwarte-Waldhoff I. Differential protome analysis of conditioned media to detect Smad4 regulated secreted biomarkers in colon cancer. Proteomics. 2005 Jul; 5 (10): 2587-601
  163. Klein W, Tromm A, Folwaczny C, Hagedorn M, Duerig N, Epplen J, Schmiegel W, Griga T. The G2964A polymorphism of the STAT6 gene in inflammatory bowel disease. Dig Liver Dis. 2005 Mar; 37 (3): 159-61.

  Versenden Drucken